FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Anxiety patents



      
           
This page is updated frequently with new Anxiety-related patent applications. Subscribe to the Anxiety RSS feed to automatically get the update: related Anxiety RSS feeds. RSS updates for this page: Anxiety RSS RSS


Date/App# patent app List of recent Anxiety-related patents
09/04/14
20140249173
 Glutamate agents in the treatment of mental disorders patent thumbnailGlutamate agents in the treatment of mental disorders
Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof.
09/04/14
20140249090
 Peptides and pharmaceutical compositions for use in the treatment by nasal administration of patients suffering from anxiety and sleep disorders patent thumbnailPeptides and pharmaceutical compositions for use in the treatment by nasal administration of patients suffering from anxiety and sleep disorders
The present invention provides peptides for use in a medicament which is administered nasally, wherein the peptide is an agonist of neuropeptide s receptor (npsr), of the receptor tgr23 and/or of vasopressin receptor-related receptor 1 (vrr1) or for use in the treatment of a patient by causing, promoting or increasing relieve or healing of phobic anxiety, avoidance anxiety, dissociative anxiety such as flashbacks, depersonalization, derealization, intrusions, vegetative symptoms related to anxiety symptoms, especially in panic attacks, in posttraumatic stress disorder, in generalised anxiety disorder and in anxiety accompanying depressive, or psychotic episodes, arousal, awakening, alertness, activity, spontaneous movement, an anxiolytic effect or a combination thereof in the patient, wherein the peptide is administered nasally or for use in the prophylaxis and/or treatment of an anxiety or sleep disorder, especially in any type of hypersomnia like idiopathic hypersomnia, wherein the peptide is administered nasally. Further provided are pharmaceutical compositions for nasal administration comprising at least one of said peptides, uses of said peptide or said pharmaceutical composition.
08/28/14
20140243363
 Methods and compositions for treating anxiety disorders or symptoms thereof patent thumbnailMethods and compositions for treating anxiety disorders or symptoms thereof
The present invention relates to methods and compositions for reducing distress dysfunction, including emotional and physical distress. The invention entails co-administration of at least one receptor switcher and at least one endorphin enhancer.
08/14/14
20140228565
 Thienopyrimidinone derivatives as mglur1 antagonists patent thumbnailThienopyrimidinone derivatives as mglur1 antagonists
Disclosed are thienopyrimidinone derivatives as antagonists that act on metabotropic glutamate receptor subtype 1. The thienopyrimidinone derivatives show pharmacological activity against metabotropic glutamate receptor-related diseases, including pain, such as neuropathic pain and migraine, psychiatric diseases, such as anxiety disorder and schizophrenia, urinary incontinence, and neurodegenerative diseases, such as parkinson's disease and alzheimer's disease.
08/14/14
20140228377
 Methylpiperidine derivative patent thumbnailMethylpiperidine derivative
A compound represented by formula (ia) or a pharmaceutically acceptable salt thereof, which acts relying on an orexin (ox) receptor antagonistic activity and is useful for the treatment or prevention of diseases such as sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, alzheimer's disease, parkinson's disease, huntington's chorea, eating disorder, head ache, migraine, pain, gastrointestinal diseases, epilepsy, inflammations, immune-related diseases, endocrine-related diseases and hypertension.. .
08/07/14
20140221395
 Deuterium-enriched alkyl sulfonamides and uses thereof patent thumbnailDeuterium-enriched alkyl sulfonamides and uses thereof
The present invention is concerned with deuterium-enriched sulfonamides of formula 1, their pharmaceutically acceptable salts and methods of use thereof for the treatment of anxiety disorders including, general anxiety disorder (gad), panic disorder (pd), post-traumatic stress disorder (ptsd), social phobia (sp), health anxiety (hypochondriasis), depression, major depressive disorders, unipolar depression, bipolar i depression disorder, bipolar ii depression disorder, treatment-resistant depression, single episodic and recurrent major depressive disorders, depression in the medically ill, attention deficit hyperactivity disorder (adhd), attention deficit disorder (add), obsessive-compulsive disorder (ocd), obsessive-compulsive personality disorder (ocpd), autism spectrum disorder (asd), schizophrenia, psychosis, epilepsy, seizures, hot flashes due to menopause, age-related macular degeneration (amd), premature ejaculation, male erectile dysfunction, sexual dysfunction, obesity, eating disorders, bulimia nervosa, anorexia nervosa, angina, migraine, pain, nociception, sleep disorders, insomnia, fibromyalgia, alcohol withdrawal, autism, rett's syndrome, cyclothymic disorder, neural injury, neurodegenerative diseases, parkinson's disease, parkinson's disease psychosis, huntington disease, alzheimer's disease, frontotemporal dementia, cognitive impairment associated with age-related dementia, alzheimer's disease, schizophrenia, psychosis, depression, pain or discomfort associated with surgery and pain or discomfort associated with medical illness.. .
07/31/14
20140213961
 Treatment of mood and/or anxiety disorders by electrical brain stimulation and/or drug infusion patent thumbnailTreatment of mood and/or anxiety disorders by electrical brain stimulation and/or drug infusion
A system and method for introducing one or more stimulating drugs and/or applying electrical stimulation to the brain to treat mood and/or anxiety disorders uses an implantable system control unit (scu), specifically an implantable signal/pulse generator (ipg) or microstimulator with one or more electrodes in the case of electrical stimulation, and an implantable pump with one or more catheters in the case of drug infusion. In cases requiring both electrical and drug stimulation, one or more scus are used.
07/31/14
20140213842
 Methods and devices for treating primary headache patent thumbnailMethods and devices for treating primary headache
Non-invasive electrical nerve stimulation devices and magnetic stimulation devices are disclosed, along with methods of treating medical disorders using energy that is delivered noninvasively by such devices. The disorders comprise migraine and other primary headaches such as cluster headaches, including sinus symptoms that resemble an immune-mediated response (“sinus” headaches), irrespective of whether those symptoms arise from an allergy that is co-morbid with the headache.
07/24/14
20140206876
 2-(substituted ethynyl)quinoline derivatives as mglur5 antagonists patent thumbnail2-(substituted ethynyl)quinoline derivatives as mglur5 antagonists
Provided is a 2-(substituted ethynyl)quinoline derivative having an mglur5 antagonistic activity and pharmaceutically acceptable salts thereof. The compound of the present invention can be useful as a medicament for treating and preventing mglur5 receptor-mediated diseases such as alzheimer's disease, senile dementia, parkinson's disease, l-dopa-induced dyskinesia, huntington's chorea, amyotrophic lateral sclerosis, multiple sclerosis, schizophrenia, anxiety disorder, depression, neuropathic pain, drug dependence, fragile x syndrome, autism, migraine and gastroesophageal reflux disease (gerd)..
07/10/14
20140194525
 Exo-s-mecamylamine formulation and use in treatment patent thumbnailExo-s-mecamylamine formulation and use in treatment
A pharmaceutical composition includes a therapeutically effective amount of exo-s-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-r-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg.
06/12/14
20140163240
Process for the synthesis of (+) and (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane
The present invention is concerned with novel processes for the preparation of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof. These compounds have pharmaceutical utility and are known to be useful for treating e.g., depression, anxiety disorders, eating disorders and urinary incontinence..
06/12/14
20140163043
Phenyl-piperazine derivatives as serotonin reuptake inhibitors
Wherein the substituents are defined in the application. The compounds are useful in the treatment of an affective disorder, including depression, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive disorder..
06/05/14
20140155952
Method of treating depression, mood disorders and anxiety disorders using neuromodulation
The present application involves a method and a system for using electrical stimulation and/or chemical stimulation to treat depression. More particularly, the method comprises surgically implanting an electrical stimulation lead and/or catheter that is in communication with a predetermined site which is coupled to a signal generator and/or infusion pump that release either an electrical signal and/or a pharmaceutical resulting in stimulation of the predetermined site thereby treating the mood and/or anxiety..
06/05/14
20140155677
Treatment of anxiety disorders by external application of ionizing radiation
Medical systems, devices, and methods provide improved radiosurgical techniques for treatment of anxiety disorders (such as post-traumatic stress disorder (ptsd), generalized anxiety disorder (gad), panic disorder, social phobia, specific phobia, and the like). Radiation can be directed from a radiation source outside the patient toward a target tissue deep within the patient's brain using a stereotactic radiosurgical platform, typically without having to impose the surgical trauma associated with accessing deep brain tissues.
05/29/14
20140148465
Compositions and methods to improve treatment of medical conditions using d-cycloserine
The invention describes methods and compositions for alleviating medical afflictions for which anxiety may cause or exacerbate the affliction. A subject suffering from the affliction is treated with a combination of a pharmaceutical compound that enhances learning, and a second pharmaceutical recognized to be useful for treatment of the affliction, wherein d-cycloserine is the pharmaceutical compound that enhances learning.
05/08/14
20140127328
Methods and compositions for treating anxiety disorders or symptoms thereof
The present invention relates to methods and compositions for reducing distress dysfunction, including emotional and physical distress. The invention entails co-administration of at least one receptor switcher and at least one endorphin enhancer.
05/01/14
20140116348
Pet carrier
The present invention discloses a pet carrier wherein the ,pet carrier is evenly perforated with ventilation holes. The pet carrier comprises four non-separable flexible panels: a bottom panel, a first-side panel, a second-side panel and a roof panel, in which the first-side panel, the second-side panel, and the roof panel can be folded onto the bottom panel to form a collapsed configuration.
04/24/14
20140113944
Bicyclo (3.1.0) hexane-2, 6-dicarboxylic acid derivatives as mglu2 receptor agonist
The present invention provides novel mglu2 agonists useful in the treatment of bipolar disorder, schizophrenia, and generalized anxiety disorder.. .
04/17/14
20140107398
Methods and devices for treating primary headache
Non-invasive electrical nerve stimulation devices and magnetic stimulation devices are disclosed, along with methods of treating medical disorders using energy that is delivered noninvasively by such devices. The disorders comprise migraine and other primary headaches such as cluster headaches, including sinus symptoms that resemble an immune-mediated response (“sinus” headaches), irrespective of whether those symptoms arise from an allergy that is co-morbid with the headache.
04/17/14
20140107397
Methods and devices for treating primary headache
Non-invasive electrical nerve stimulation devices and magnetic stimulation devices are disclosed, along with methods of treating medical disorders using energy that is delivered noninvasively by such devices. The disorders comprise migraine and other primary headaches such as cluster headaches, including sinus symptoms that resemble an immune-mediated response (“sinus” headaches), irrespective of whether those symptoms arise from an allergy that is co-morbid with the headache.
04/17/14
20140107108
Compositions comprising alprazolam for treating primary insomnia and insomnia associated with anxiety states and process for preparing them
Disclosed is a composition comprising alprazolam for treating primary insomnia and insomnia associated with anxiety states and the corresponding use and method comprising the administration of alprazolam sublingual tablets having a disintegration time lower than 30 seconds and having the alprazolam preferably in non-crystalline or partially crystalline form according to the x-ray diffraction crystallography expanded for the position delta 9-12.5 (2 theta), to a patient suffering from said disorder. There is also disclosed a method for preparing a composition according to the invention, where the alprazolam is solved in a pharmaceutical acceptable solvent and a binder, preferably polyvinylpyrrolidone, is incorporated to the solution.
04/10/14
20140096767
Nasal aroma breathing pipe
The claimed invention is an apparatus to assist and encourage a person to take long, deep and steady breaths. The invention is designed to provide improved health for the user by fostering; improved breathing and relaxation, positive smell association, calmer clearer thinking, reduced stress and anxiety, as well as providing a substitute for potentially harmful habits such as smoking, over-eating, over-drinking and other forms of drug abuse.
03/27/14
20140088104
Novel small-molecules as therapeutics
The present invention provides compounds of formula (i), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful in treating central nervous system disorders, such as anxiety disorders or depression..
03/20/14
20140081071
Methods and devices for treating primary headache
Non-invasive electrical nerve stimulation devices and magnetic stimulation devices are disclosed, along with methods of treating medical disorders using energy that is delivered noninvasively by such devices. The disorders comprise migraine and other primary headaches such as cluster headaches, including sinus symptoms that resemble an immune-mediated response (“sinus” headaches), irrespective of whether those symptoms arise from an allergy that is co-morbid with the headache.
03/20/14
20140081025
Heteroaromatic ring derivative
Or a pharmaceutically acceptable salt thereof is based on orexin (ox) receptor antagonist activity, is useful in the treatment and prevention of illnesses including sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependency, alzheimer's disease, parkinson's disease, huntington's chorea, eating disorders, pain, gastrointestinal disease, epilepsy, inflammation, immunological disease, endocrinological related disease, and hypertension.. .
03/06/14
20140066504
Analogs and prodrugs of bumetanide; compositions and methods of use
Novel analogs and prodrugs of the loop diuretic bumetanide are described. Pharmaceutical compositions containing bumetanide analogs and prodrugs are also described.
02/13/14
20140045839
Novel anxiolytic compounds
Which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.. .
01/23/14
20140024658
Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypertension, cerebral disorders, chronic pain, acromegaly, hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation.. .
01/16/14
20140018549
Use of d-serine derivatives for the treatment of anxiety disorders
Compounds of formula i are useful for the treatment of anxiety disorders such as generalized anxiety disorder (gad), panic attack, post traumatic stress disorder (ptsd), obsessive compulsive disorder (ocd) and social phobias, wherein: a is chosen from: aryl or heteroaryl, a being optionally substituted with up to 5 independently-selected groups r8; r1 is chosen from: alkyl or haloalkyl; r2 is chosen from: h, c(o)r6, c(o)or6, so2r6 or c(o)nr6r7; r3, r4 and r5 are independently chosen from: h or alkyl; r6 and r7 are independently chosen from: h or alkyl; and r8 is chosen from: oh, cn, halo, alkyl, alkoxy, haloalkyl, haloalkoxy, c(o)r6, c(o)or6, so2r6 or c(o)nr6r7.. .
12/26/13
20130345241
Dihydrooxazol-2-amine derivatives
Or to a pharmaceutically acceptable acid addition salt thereof. Compounds of formula i have a good affinity to the trace amine associated receptors (taars), especially for taar1.
12/12/13
20130331571
Glycine transporter-inhibiting substances
The compounds of the present invention are useful in the prevention or treatment of diseases such as schizophrenia, alzheimer's disease, cognitive impairment, dementia, anxiety disorders (e.g., generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, acute stress disorder), depression, drug dependence, spasm, tremor, pain, parkinson's disease, attention deficit hyperactivity disorder, bipolar disorder, eating disorder, or sleep disorders, which is based on the glycine uptake-inhibiting action.. .
10/24/13
20130281465
Pyrazole derivative
A compound represented by formula (ia) or a pharmaceutically acceptable salt thereof, which is useful for the treatment or prevention of diseases such sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, alzheimer's disease, parkinson's disease, huntington's chorea, eating disorder, pain, gastrointestinal diseases, epilepsy, inflammation, immune-related diseases, endocrine-related diseases, and hypertension, and of which the action relies on an orexin (ox) receptor antagonistic activity.. .
08/15/13
20130210783
Neuroactive steroid compositions and methods of use therefor
Provided are methods for ameliorating a symptom of a neuropsychiatric disorder. Also provided are methods for ameliorating at least one symptom resulting from tobacco cessation; and for ameliorating a symptom of alzheimer's disease or other cognitive disorder; of schizophrenia, schizoaffective disorder, or other psychotic disorder; of a depressive disorder; of bipolar disorder; of post-traumatic stress disorder or other anxiety disorder; of a pain disorder; or of traumatic brain injury.
08/15/13
20130210714
Protein-bound tryptophan food composition
A composition comprising at least partially defatted meal from a plant source containing protein-bound tryptophan, which plant source has been processed to at least partially remove oil contained therein to yield said meal having a natural source of tryptophan greater than its plant source, a carbohydrate source having a high glycemic index and a physiologically-acceptable diluent or carrier therefor for inducing sleep, alleviating an anxiety disorder, depression, obsessive compulsive aggression, chronic pain or eating disorder, in a human in need thereof, wherein said composition is in the form of a food bar further comprising a puffed cereal. The composition provides improved sleep characteristics..
08/01/13
20130197217
1, 2, 4-triazolone derivative
The present invention provides a 1,2,4-triazolone derivative represented by formula (1a) having an antagonistic activity on the arginine-vasopressin 1b receptor or a pharmaceutically acceptable salt thereof and provides a pharmaceutical composition comprising the compound or the salt as an active ingredient, in particular, a therapeutic or preventive agent exhibiting favorable pharmacokinetics in a disease such as mood disorder, anxiety disorder, schizophrenia, alzheimer's disease, parkinson's disease, huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, or alopecia.. .
07/18/13
20130184639
Treatment of mood and/or anxiety disorders by electrical brain stimulation and/or drug infusion
A system and method for introducing one or more stimulating drugs and/or applying electrical stimulation to the brain to treat mood and/or anxiety disorders uses an implantable system control unit (scu), specifically an implantable signal/pulse generator (ipg) or microstimulator with one or more electrodes in the case of electrical stimulation, and an implantable pump with one or more catheters in the case of drug infusion. In cases requiring both electrical and drug stimulation, one or more scus are used.
07/18/13
20130184460
Glycine transporter inhibiting substances
The present invention aims to provide novel compounds of formula [i] or pharmaceutically acceptable salts thereof that are based on a glycine uptake inhibiting action and which are useful in the prevention or treatment of such diseases as schizophrenia, alzheimer's disease, cognitive dysfunction, dementia, anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, posttraumatic stress disorder, specific phobia, acute stress disorder, etc.), depression, drug addiction, spasm, tremor, pain, and sleep disorder:. .
07/18/13
20130184294
Pyrimidones for treatment of potassium channel related diseases
The present invention relates to compounds of formula i as described herein or a pharmaceutically acceptable salt thereof, pharmaceutical composition comprising a compound of formula i or a pharmaceutically acceptable salt thereof and methods of treating a disease, disorder, or condition of the central nervous system, including bipolar disorder, depressive disorders, anxiety disorders, cognitive disorders, pain disorders, urogenital disorders, and epilepsy, among the other diseases, disorders or conditions discussed herein as mono-therapy or in combination with another active pharmaceutical ingredient.. .


Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Anxiety for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Anxiety with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



1.3959

3905

4 - 0 - 73